0001437749-21-020569.txt : 20210820 0001437749-21-020569.hdr.sgml : 20210820 20210820090030 ACCESSION NUMBER: 0001437749-21-020569 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210819 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210820 DATE AS OF CHANGE: 20210820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GeoVax Labs, Inc. CENTRAL INDEX KEY: 0000832489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870455038 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39563 FILM NUMBER: 211191877 BUSINESS ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: GA ZIP: 30080 BUSINESS PHONE: 678-384-7220 MAIL ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: GA ZIP: 30080 FORMER COMPANY: FORMER CONFORMED NAME: Geovax Labs, Inc. DATE OF NAME CHANGE: 20061002 FORMER COMPANY: FORMER CONFORMED NAME: DAUPHIN TECHNOLOGY INC DATE OF NAME CHANGE: 19940826 FORMER COMPANY: FORMER CONFORMED NAME: SUCCESSO INC DATE OF NAME CHANGE: 19910410 8-K 1 govx20210818_8k.htm FORM 8-K govx20210818_8k.htm
false 0000832489 0000832489 2021-08-19 2021-08-19 0000832489 govx:CommonStockParValue0001PerShareCustomMember 2021-08-19 2021-08-19 0000832489 govx:WarrantsToPurchaseCommonStockCustomMember 2021-08-19 2021-08-19
 
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  August 19, 2021
 
 
GEOVAX LABS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-39563
  
87-0455038
(State or other jurisdiction of
incorporation or organization)
  
(Commission File No.)
  
(IRS Employee Identification No.)
 
1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
(Address of principal executive offices) (Zip code)
 
(678) 384-7220
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
GOVX
The Nasdaq Capital Market
Warrants to Purchase Common Stock
GOVXW
The Nasdaq Capital Market
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
This Form 8-K and other reports filed by GeoVax Labs, Inc. (the “Registrant” or the “Company”) from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well as estimates and assumptions made by the Registrant’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant’s management identify forward looking statements.  Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant’s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Registrant does not undertake to update its forward-looking statements.
 
Item 8.01
Other Events.
 
On August 19, 2021, we issued a press release reporting the presentation of data from ongoing studies of our preventive vaccine against COVID-19. The presentation titled, “Design of a Universal SARS-CoV-2 Vaccine Against Evolving Variants,” was delivered virtually by Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer, during the European Society of Medicine (ESMED) General Assembly, being held August 19-21 in Berlin, Germany.
 
A copy of the press release is attached to this Current Report. Dr. Newman’s full presentation is available on GeoVax’s website at www.geovax.com/investors/events.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)     Exhibits
Exhibit No.
Description
99.1
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
   
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 20, 2021
 
 
GEOVAX LABS, INC.
  
     
     
 
By:
/s/ Mark W. Reynolds
  
   
Mark W. Reynolds
  
   
Chief Financial Officer
  
 
 
 
 EX-99.1 2 ex_277322.htm EXHIBIT 99.1 ex_277322.htm

Exhibit 99.1

 

img01.jpg
 

GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly

 

GeoVax Vaccine Being Developed as a Universal Vaccine to

Address Evolving SARS-CoV-2 Variants

 

ATLANTA, GA, August 19, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today presented data from ongoing studies of its preventive vaccine against COVID-19. The presentation titled, “Design of a Universal SARS-CoV-2 Vaccine Against Evolving Variants,” was delivered virtually by Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer, during the European Society of Medicine (ESMED) General Assembly, being held August 19-21 in Berlin, Germany.

 

First-generation SARS-CoV-2 vaccines were rapidly developed and have proven highly efficacious in the human population and were designed to encode the prefusion stabilized Spike protein (S) with the goal of inducing high levels of neutralizing antibodies. However, potential limitations of narrowly focusing on S are becoming apparent with emerging variants that partially escape neutralization by vaccine induced antibodies. Thus, the effectiveness of these vaccines against new SARS-CoV-2 variants and future coronavirus spillover events remains in question.

 

Using its novel Modified Virus Ankara - Virus Like Particle (GV-MVA-VLPTM) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple structural and nonstructural proteins from the target pathogen. The GV-MVA-VLPTM platform is known to elicit a balanced humoral (antibody) and cellular response against a range of immunogens, possibly making immune escape against emerging variants less likely. Expression of the SARS-CoV-2 spike, membrane and envelope proteins by MVA supports the in vivo formation of virus like particles, or VLPs, which induce both antibody and T-cell responses. Incorporation of sequence-conserved nonstructural proteins can provide targets for T-cell responses to increase the breadth and function of vaccine-induced immune responses. This strategy provides the basis for generating a universal vaccine with augmented potential to alleviate the burden of disease caused by circulating coronaviruses.

 

In his talk, Dr. Newman discussed GeoVax’s vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented stability and protein expression data for the Company’s initial vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins. Dr. Newman also presented vaccine efficacy and immunogenicity data for GEO-CM02 from hamster and transgenic mice studies to date.

Dr. Newman’s presentation is available on GeoVax’s website at www.geovax.com/investors/events.

 

Dr. Newman commented, “Our studies to date support the use of MVA as a vector for the design and production of next-generation vaccines encoding multiple coronavirus proteins, using the S protein as the antibody target and the M and E proteins as T-cell targets. The combination of S, M and E protein expression supports VLP formation and optimal immunogenicity. In our studies, we observed the induction of functional antibodies and T-cell responses that mediate protection from infection and pathogenesis.”

 

David Dodd, GeoVax President and CEO, further commented, “The presentation of data from this study further validates our platform and approach to addressing COVID-19 and its variants. Our vaccines under development are intended to be used as either a primary vaccine or to boost other COVID-19 vaccines as part of vaccination strategies to provide immunity to a range of coronavirus variants. We believe a critical and significant opportunity exists for a pan-coronavirus vaccine with the attributes the GV-MVA-VLPTM technology can offer.”

 

 
 

 

About GeoVax

 

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

 

GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia; human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of a collaborative effort toward a functional cure for HIV.

 

Forward-Looking Statements

 

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from additional tests of its preventive vaccine against SARS-CoV-2, GeoVax’s vaccines can provoke the desired immune responses, and those vaccines can be used effectively as a primary or booster to other vaccines, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

 

Further information on our risk factors is contained in our registration statement on Form S-1 and the periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by U.S. federal securities law. 

 

Contact:

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

 

###

 
 EX-101.SCH 3 govx-20210819.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 govx-20210819_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 govx-20210819_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key Class of Stock [Axis] Class of Stock [Domain] CommonStockParValue0001PerShare Custom [Member] WarrantsToPurchaseCommonStock Custom [Member] EX-101.PRE 6 govx-20210819_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 img01.jpg begin 644 img01.jpg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end XML 8 govx20210818_8k_htm.xml IDEA: XBRL DOCUMENT 0000832489 2021-08-19 2021-08-19 0000832489 govx:CommonStockParValue0001PerShareCustomMember 2021-08-19 2021-08-19 0000832489 govx:WarrantsToPurchaseCommonStockCustomMember 2021-08-19 2021-08-19 false 0000832489 8-K 2021-08-19 GEOVAX LABS, INC. DE 001-39563 87-0455038 1900 Lake Park Drive, Suite 380 Smyrna GA 30080 678 384-7220 false false false false Common Stock, par value $0.001 per share GOVX NASDAQ Warrants to Purchase Common Stock GOVXW NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Aug. 19, 2021
Document Information [Line Items]  
Entity, Registrant Name GEOVAX LABS, INC.
Document, Type 8-K
Document, Period End Date Aug. 19, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39563
Entity, Tax Identification Number 87-0455038
Entity, Address, Address Line One 1900 Lake Park Drive, Suite 380
Entity, Address, City or Town Smyrna
Entity, Address, State or Province GA
Entity, Address, Postal Zip Code 30080
City Area Code 678
Local Phone Number 384-7220
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000832489
CommonStockParValue0001PerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GOVX
Security Exchange Name NASDAQ
WarrantsToPurchaseCommonStock Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants to Purchase Common Stock
Trading Symbol GOVXW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.govx.com/20210819/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports govx20210818_8k.htm ex_277322.htm govx-20210819.xsd govx-20210819_def.xml govx-20210819_lab.xml govx-20210819_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "govx20210818_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "govx-20210819_def.xml" ] }, "inline": { "local": [ "govx20210818_8k.htm" ] }, "labelLink": { "local": [ "govx-20210819_lab.xml" ] }, "presentationLink": { "local": [ "govx-20210819_pre.xml" ] }, "schema": { "local": [ "govx-20210819.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 2, "memberStandard": 0, "nsprefix": "govx", "nsuri": "http://www.govx.com/20210819", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "govx20210818_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.govx.com/20210819/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "govx20210818_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "govx_CommonStockParValue0001PerShareCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockParValue0001PerShare Custom [Member]" } } }, "localname": "CommonStockParValue0001PerShareCustomMember", "nsuri": "http://www.govx.com/20210819", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "govx_WarrantsToPurchaseCommonStockCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsToPurchaseCommonStock Custom [Member]" } } }, "localname": "WarrantsToPurchaseCommonStockCustomMember", "nsuri": "http://www.govx.com/20210819", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.govx.com/20210819/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-21-020569-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-020569-xbrl.zip M4$L#!!0 ( I(%%/\UI4S7Q +TV - 97A?,C F1$E2TDNKFS)5;;$(09H-)[N?KH;/IK7B_+X:*YDUKDMU MK&[^]^#%BV\/#H;X]F@W/'SV%WS_'UDFSI113M:J$).UN)PWIE#NQ"Z4^&1= M+4N1B9>[^Z]V#_8.]L7!X=[?#@_^+L;G(LN.CQ:JEB*?2^=5_=U64T^SEUOQ MJ9$+]=W6U+J%K+-"U2JOM35;(K>F5@:C:U6J:FZ-^L[8K>-G1[M!YJ.)+=;" MU^N27S=UYO4OZG!_KZI'_'$J%[I<'_[U4B^4%Q_42GRV"VG^.JID46@S.]S3 M1@SWM1G1K%6::B'=3)ML8NO:+@[%7G4S$K6ZJ3-9ZIDY%$[/YO5(Q&&UK7@, M=D.+WI(G"B#N2# 0_&0@O')Z.A*=](+$QUR3X].;N9[H6KQZ-=P_VIT<'^W2 M*/RHCI_]!FE+-?W:PGYC)KX:W9:OT,O;$M*Z=7PY+?7-SXVM1QOKA8=WEL$9 M'>G%3,@2B, O>_O#GZK9EO N[W_&^ECZ:TF0=AJ7J.Y3X,9DHQXR7R9D+J73 MTM2'AD!?CGKGE0/QRHVBQ''?D^,S9:_DC?CDE,< +UY_O'IWDNV_$EZ\6DW(= M(%9]<5MWK>@^D]O8V*UM).5]>8T'5'?PNU5WI)/VDJZ^5S!^<:*6JH2>"B&] MD.)'HY?*>6@D#:NM.-K5QX\IYFL)/2X*G+87ITM;+DG@B_'GB^RUO?[R8']_).+YOI<3>*EW)A^*[0_2%_+G0W'V\>I?.P.<[T1;1):YL:6=K1%; M%I4TB!Z5RC6D^(44C&A0!%#0IWF#G8AE ,08@J12Y,K)_1BT1@+2W.RTN08 M:UO(M:B"<0)0!1GCU-F%L&9F:3)?-P6&DB5JF"^&+C$4B$L+"#F3VF"#R;*' M"+ JS2DI(@J.QL6 MWVP-SI1'MJC*?OHO862,/4X3MTB*<%GP#-!@2N80*%* MF@/B+[6K&UF6:PKSY])=BW\,Z7"ACX'X-!^># =1Y7P +T;P1W.MIN("[@:[ MFNIH3&X+Q2\ F-/&TTA?RXF&!6'(1:6O>;$: M1R:V+W;$2M=S'C^S.%-"ORF:G,\3LH"<0%2V"J.:VB5#A'HTR!T,9BC>VA4& M 4B5)38(8Q6E7NA@$N%5Z9Q=85]3FT,DO$]:$A+"3Q0,G6>L*GP&XV&!U$*1 MAF*L?*7+$@?I!'L/+YQ:T$1T MB#\WRI.03]$$?N1#);]IL/M2G$/A4PWM7[%:QN9:.HGD(WQ\3QC\1$>9EW K M9U?9^=4XNWK_Z<@WK<10(KZ795P6O'@$1Z*RN2)RC\B]]Y\]R8GD7IX?[6*" MXQU1P40H6TE.$";F^T87309+4:XT(URZ[NS5#4).'>PIH$A,G)5%BBL:?K&> M.]O /+3)RV!DP-"B*6M=84N8M\D!#E@" <7 #+HGT?A\"#\$QAJJ5 3N>F[A M1D)<^:.UTBI%:"^NC5T9]A6%#H+\C.6Q-R.AK/>"8%5E24\CP.B M?87]=.%0PJV9F6+7P6$76_#D#+S7B Y(;*X9'/2=2G:;7KYKYR499 F$E.NA M.+VA\)KT2[KJ&:,G7S80"P0A2*!83&7"(7=:I@!Y-1900844V/,DX&XPR*5> M6J)G(B2V<9%@R"6[R0A1[ ;XP$G@E]5?W+C!35*@D^!V3' M.BS=+N 5/ %4G>4TPBW5%P&2D\-'7-!%PHAGI&XN$H":.R5]&[U5)C]C!EXPK%DA7:L_2Y;'PH7N3:Y1SJL$K/Q4+()^@_WU'DAYIE M>3T0)RYQ.5(+ B9I9(/-)5W?Y\AZ#+E_/'=9">.CX\21)M3K^#QP!-698"#- M6('.[G7@YZU$&GY1]U \!8:;\!"STX_9J_/]PZ2]022$E 5" F(R !$,QKR M]GGP.:?)F+=/=UJK&/;U(TMO>SM(:T?Z%#;2.B7R=.MN$TFJX(?G?-Z RDI-O(;! M@3X=-<>KU6HX4W8I;X8@7KL:*O:U=7XW$):CW>;X*1I8#S/8=O!,;9KVL7&; M9YSB!6,47H<3(801+D0L00\ H&0)T0:CT<"S)G=K2*A>7M Q##( LL^6,?1) M9$+Z0 2NS&;2VJ,,=M-&G4@>&+=X?AXLIPLB&!_C10PA@5Y "Q-MVJ!T,=A\ MLV_X;?!$#.Q%2QIOJUKC #:LC,*>L)U:8?E0X22&.Y*30U!:/<4HYDN)KM\; M3T,:L$!*2H?$HH99V(BUF<:/?!B13^%X_##FT4\1VH!-(4YL4;1TEXJ0B-LF MP.+UZ<Y\FCF[NON0/=2GLP\_GF^T M'V[_>'8T=VGA3^.ST^S[SZ?C'[+QF\O3SX=@,BNY]B/ %I38'5)*H&X),Q+Q M\,0!-9!R'!&&/=_C/WA/YMF^L' M%?!P4^8W=[728<>3W]S*GU@4G]BFCJ[XB9;^[Y;SB80"%,@"R.T@E8"/O+^@ M_T !/Q8%4AB'^XMYX:WB?F!%,I::$.4#^>]J3CR?EK'LE-U;=(I.$5:E.41*-BF2"756#=B ;2N34W$J@8VDN$B-&$DDAD5*JC M>('.R%!(YTAGF6-UA914_JV0Q"% .94KO4RL,"Z1&A%][DG5BHUW0Y4^A3O% M^D2"@Q1'M,0SS4!$4V 4%R1:6@53!-M+63E7/V)IVJ9:5ULGDFZ1"JNISN#7 M2+$6%$6Q#8M@^ N2P]AH&82W@45GRWY5K%T\[#*>&U#D]+([N% LB=6L E*S M.C?*&VTIG9B!Q\9)3H[IU%?)$%F5:5@SK ].5TL5:4#2N9=3:HS010F9(V(@ M=NO5^Q&Z"V:1):DO0A8)NV.VJ 4\ZZI M#A@M:XSG0!PT\T]%]0L36W@#\0^X)A.V/&X\-TGD*'K%@7#B7(NCE4BPU*Z\#*]]4/7*NFNQ_?;J\D.ODY1RYRCC!QESNW?8KZZ9 MNM).E2SQPO:'=V]WAIM%B[[R*+1PG2<2=DGDIY03KJDNN=K#F;I=24=GT,LF M\X91YVB^IVB X1["&^MHZ]E[:[G4?H%$3BW4$[]]H(^Y6.U4&2K'F(-;;=.H MC3)JP[?:P-@9OJ&'B9WIXP@Y3.?%A*@%]1\0]$TT=""\\"*-1+Z,D3'!&[1/ M]^GIQB!:/PD#<#X\>"'7#P^@WN&"JJD/CB(E:-,\,HH82:ZK1V<+B??#8_S< M-N4C8TB;C\G]Z"2!#CRR4&HU/+*OU&!Z>-A*EX],%#J%&T-"JA_(15=#\X,8 M:-:$V!@)**)M5CBX;@.T/X!C+C+PK8% 7D/O^@'<,V4MUQ1WJ623XG00/[;I M8_GRIT"V\)FSF-CCCMUL[B>!/!H.134F*2*%7755#T!92&ZO\V+=>("ST(%& M0BF(JAP&$*Q">12Z:.VO[6?<7M$H56#WXYPNO[23T(*@_E.0 ;(0%RX(Q.J5 M]2HT:4F](9QZU==-T:C A":XQ*"(#UK[EHU'5L!E]P6+?8+_%4>ZW:FK2[ MI\,WB(5BV[_L0"^GPEI[,0(JY&)WJJXAB'))33%EMK$2&&;XHGB:$Z%0+N^E M@K)0/Q/1IC46H,Q3*KC=8>M8)F9\70H5M4\21Y8929UIZ- (JZ&^F*[=)$Z2 M%++)VSG1@6M5W*DVANZQ/*)K\@ND+\H$F%P$4@7U_;I7^RJ.IQ^3'8;H-%D@ M1..9OZS>6].&U) 4.*,,S>+,N!R[)*IF\"4XL%O'(BK2%.@S7D *G%)U]6,G M-1V PRD%I6HJY<-X M(0]8?>]2#H$-05T'K#7VWC2R$!6T+)&1(JKGW ME ;M[V7_S:/2IQ_:$,0Q<8J":@4 ?.S=P".DI@W3NT/Q)FK MM? 6$ F.>&& RM#W@YCU'E, M46P=+L:H&,5PCO0U_1S$'@JM9FR=KMD$1]3$M@7=V*SIKD64=<&,@;LKM42$ M %#M!(<<+ZWBE08?'-DS5??;]LV$'X?L/^!U;M,*T&&6(A3!,E6&$BZH$ZWOA4T=;:)2J3& M'XWSW^](2;:4R(GL#L6>1)'?Q_ON>#R=+MYOBIQ\!VV$DM,H&8TC I*K3,C5 M-/H\CZ_FU[-91(QE,F.YDC"-I(K>7_[ZR\6[./X $C2SD)'%$WE8.YF!OE$% MD'NE+G).KNSCV_(W)4L/74#""(J1)-PN=BVFT MMK9,*7U\?!SYF9'2*]QA?$J%]#(X1 W>9!WTXVF#3>B7N]MYV'L+SH7\U@=/ M)I,)#:L-5"HI7=$O)+.:VJ<2*()B1($6O.$96^HM*S ,\-%*?:=^)42A@;X0 MT_74+R^8V7HZ0$Y7B@=DMBNFWOV,5HL-- /1+QH7.IJYBG^+&U[LI^+D)#Y-1F@ZH@=KF%"MCK:_*Y/#\JN&^\'Q/G>+ M[3"GVYSMV]$26@5\D/DM/HRZ9FO#3$IEPQZ-%%:60BZ5?_4?V[3YXGZ")0G- M0,HT]X7K]9:!EEJ5H*T T_YHAPW6&I;3R-?^N*G[7W.V&.%7J8&\,-"MWZ%P M(@7RVYV\ANMO\S0R&-,E!H.]08I!ML!=I@_ MGOJ 2T1@ZXK?91MZBCA3W(4!=MDQ/H5]BGUZZB+L'Q'/^_QI]GI740D;ONM6 MU>YDJI9I2&=Z.1Z/L;^_J6VTAU58P:'])J1M$PA;&:L:Q/;3:8=KYH_9G M];4)$,:G"L^L?<2^*DZC-S BQW+@D[/:VCBT):SSJQ^T@YVNFX=H9JXH[*!:@&P\T7^-% M:/G3Y^XAA)_H+-W]?./KOU!+ P04 " *2!13T1'3#HP% #E- %0 M &=O=G@M,C R,3 X,3E?9&5F+GAM;-5;76_B.!1]7VG_0S;SG(;0[6Z+AADA MVAFA;:>H,#NK?:E,<@&KCHULI\"_7SM\E YQ8CX295\@),?V.=?7US>^XN/G M14R<5^ ",]IV@XN&ZP -683II.U^'WB=0;?7;H]P?2EI3]&2("C>%"1_FR[4REG+=^?S^<7BQ$G%XQ/5!^-2W^#=M=P_322 MVP:[X"M_]7 +W>MZ?IEB@YN;&S]]NH4*G 54G0;^/P_W@W *,?(PU48)-1>! M6R*]><]")%-+%DIPC C]R]O /'W+"YK>97"Q$)&[-1SB(6<$GF#LK"^_/_7V M+8&I]",<^VN,CPA1A-,>IAS&1J(;\^GQK_3('W9:RN5,^8' \8R ZY]**6(Q MPM2+(1X!/Y)<9A]GIHECH'J9>*O!CF5JZ.:\9*>J-QXF(_"VXQW)-Z>GTNP+ M8Y00>;J!W_=CH+OA^C-1/=*$O2XN0A:G$:QQK4)92E4M? EJ%*GF,$S2"Q4> M/?6-Y5(%AC'C<1H'WDO0O7F;GE*N!W=DT*"48HHU\%[]7&,UU5+4K$C 0H** M]SLAB;!P;\K$9LH%A)J 'P%.Q]<7J3%6DP;X^2X=\/;=JB!H!*3MFAZOF! = M=1G?L4=U3+*=[.R,;M@IUQ)V+/?@)3&]APDB MJSGL+' 6.0.B9,L-5?.I*P]T2.VRA$J^[++(3-2J5:F\OV "WY+=M&F/Y#ZD M5$9#M.A%>O<9XU4V74"O %\JUTX4<1!B_:4C6&#DF8.M@F-773[R(9N;MS0C ML@I^J?<_\CYGKWCU6I5+T@"O@FF?J92)_(MGN4L[#UP22SUQ'0[(P"OK<5E[ MK.J0]*>,FF.+"5(2HQ\<2Y6P=ED<)W0=*++V_EQ<2=P&C.!0I>]T\J"IG/2[;.W2*<(CH!0YZ7!RMU#[B+@4^4 M,;YR-I=3Y48 MK67 '<5MC,0H/21*A#=!:+8B"$2*S9V4J=<(UD>K']:WGP>;\Y N04(\C@>2 MA2\9;XK6^(KY[]+(/,,H!OY_&!][_K)_%J?O/.M]0;^(J?[[B/^-2 *-1B-0 M+[J#*5+;1B(DBQ\@(Z4YMOF)A'\@KE]SQ9#U$ZY"H8 =#D5T#VYL(OMV_MCA MH<.XVDG;;D.U2L]F6R%A J*V*WFR#=+K8]_CS]W'G,7YQS6LZ.!0#5$D(CB[ MB/?^>I2*;*>W4-.L8DKLXR*SCT46XBXKF:HSJ]_,64SLU)VJPIAY%J%'[G&GS>CZ)J,2%O*.I![4 M=@5,],7!AMBIO.=Z\?U> 84=4A*JQ

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end